Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced that Mary Tagliaferri, M.D., has joined its Board of Directors. A biotech industry veteran, Dr. Tagliaferri is Chief Medical Officer at Nektar Therapeutics, where she heads clinical development strategy for the company’s immuno-oncology portfolio, as well as strategic alliances, and medical affairs.

“Mary’s track record as a physician, her drug development and regulatory experience, and her distinguished expertise in oncology and related therapeutic areas will enrich our board as we advance potential first- and best-in-class cancer therapies,” said Tom Miller, PhD, Iambic’s chief executive officer. “Mary will provide invaluable support to IAM1363, our lead clinical program for the treatment of HER2 cancers, along with our growing portfolio that includes a novel CDK2/4 inhibitor, an allosteric inhibitor for KIF18a, and additional new programs.”

“Iambic is already demonstrating the true promise of artificial intelligence for drug discovery, using its platform to bring forward highly differentiated and promising drug candidates that may lead to important advances in the treatment of devastating cancers and other disease areas,” said Dr. Tagliaferri. “The power of the Iambic platform is demonstrated both in the pace in which it can move new programs to clinic but also in its ability to do so across protein classes and target types, surpassing what was possible with traditional discovery methods.”

Prior to joining Nektar, Dr. Tagliaferri was a clinical and regulatory consultant to InterMune, served as Chief Medical Officer at KangLaiTe USA, and was Co-Founder and President and Chief Medical Officer of BioNovo, where she led the company's clinical drug development strategy and global regulatory affairs. In 2012, Dr. Tagliaferri received the State of California Woman of the Year award for her advancements of clinical research in women's health and her mentorship of women in the biotechnology field. She received her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF).

About the Iambic Therapeutics Physics-Informed AI-Driven Discovery Platform

The Iambic Therapeutics AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Iambic NeuralPLexer, which provides state-of-the-art structural predictions of protein-ligand complexes. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform’s algorithms enable identification of new chemical mechanisms for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic windows, and exploration of the chemical space to discover candidates for development with highly differentiated properties. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

About Iambic Therapeutics

Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905485740/en/